Industry Research Reports

Home > Reports > Pharma & Healthcare > Global and United States Flu RNA Vaccines Market Report & Forecast 2022-2028

Global and United States Flu RNA Vaccines Market Report & Forecast 2022-2028

Industry: Pharma & Healthcare

Published: 2022-05-09

Pages: 104 Pages

Report ld: 355758

Description
Table of Contents
Table of Figures
PDF Download

Description
Table of Contents
Table of Figures
PDF Download

The major advantage of Flu RNA Vaccines is that scientist need not to use the live cells for the vaccine preparation as such the RNA can be produced in the laboratory from a DNA template using readily available materials which can be a easy and fast weapon to fight against the new outbreaks and the existing infectious diseases.

Market Analysis and Insights: Global and United States Flu RNA Vaccines Market

This report focuses on global and United States Flu RNA Vaccines market, also covers the segmentation data of other regions in regional level and county level.

Due to the COVID-19 pandemic, the global Flu RNA Vaccines market size is estimated to be worth US$ million in 2022 and is forecast to a readjusted size of US$ million by 2028 with a CAGR of % during the forecast period 2022-2028. Fully considering the economic change by this health crisis, by Type, Non-Replicating mRNA accounting for % of the Flu RNA Vaccines global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR from 2022 to 2028. While by Application, Hospitals was the leading segment, accounting for over percent market share in 2021, and altered to an % CAGR throughout this forecast period.

In United States the Flu RNA Vaccines market size is expected to grow from US$ million in 2021 to US$ million by 2028, at a CAGR of % during the forecast period 2022-2028.

Global Flu RNA Vaccines Scope and Market Size
Flu RNA Vaccines market is segmented by region (country), players, by Type and by Application. Players, stakeholders, and other participants in the global Flu RNA Vaccines market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type and by Application for the period 2017-2028.

For United States market, this report focuses on the Flu RNA Vaccines market size by players, by Type and by Application, for the period 2017-2028. The key players include the global and local players, which play important roles in United States.

Segment by Type
Non-Replicating mRNA
In Vivo Self-Replicating mRNA
In Vitro Dendritic Cell Non-Replicating mRNA Vaccine
Others

Segment by Application
Hospitals
Vaccination Center
Specialized Clinics
Hospital Pharmacy
Others

By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE

By Company
Sanofi Pasteur Inc.
AstraZeneca
CSL Ltd.
Abbott
GlaxoSmithKline Plc.
Serum Institute of India Pvt. Ltd.
Pfizer
BioNTech
F.Hoffman La Roche Ltd
Novartis
Sinnovac Biotech Ltd
Moderna Therapeutics
CureVac

 1 Study Coverage
    1.1 Flu RNA Vaccines Product Introduction
    1.2 Global Flu RNA Vaccines Outlook 2017 VS 2022 VS 2028
        1.2.1 Global Flu RNA Vaccines Sales in US$ Million for the Year 2017-2028
        1.2.2 Global Flu RNA Vaccines Sales in Volume for the Year 2017-2028
    1.3 United States Flu RNA Vaccines Outlook 2017 VS 2022 VS 2028
        1.3.1 United States Flu RNA Vaccines Sales in US$ Million for the Year 2017-2028
        1.3.2 United States Flu RNA Vaccines Sales in Volume for the Year 2017-2028
    1.4 Flu RNA Vaccines Market Size, United States VS Global, 2017 VS 2022 VS 2028
        1.4.1 The Market Share of United States Flu RNA Vaccines in Global, 2017 VS 2022 VS 2028
        1.4.2 The Growth Rate of Flu RNA Vaccines Market Size, United States VS Global, 2017 VS 2022 VS 2028
    1.5 Flu RNA Vaccines Market Dynamics
        1.5.1 Flu RNA Vaccines Industry Trends
        1.5.2 Flu RNA Vaccines Market Drivers
        1.5.3 Flu RNA Vaccines Market Challenges
        1.5.4 Flu RNA Vaccines Market Restraints
    1.6 Study Objectives
    1.7 Years Considered

 2 Market by Type
    2.1 Flu RNA Vaccines Market Segment by Type
        2.1.1 Non-Replicating mRNA
        2.1.2 In Vivo Self-Replicating mRNA
        2.1.3 In Vitro Dendritic Cell Non-Replicating mRNA Vaccine
        2.1.4 Others
    2.2 Global Flu RNA Vaccines Market Size by Type
        2.2.1 Global Flu RNA Vaccines Sales in Value, by Type (2017, 2022 & 2028)
        2.2.2 Global Flu RNA Vaccines Sales in Volume, by Type (2017, 2022 & 2028)
        2.2.3 Global Flu RNA Vaccines Average Selling Price (ASP) by Type (2017, 2022 & 2028)
    2.3 United States Flu RNA Vaccines Market Size by Type
        2.3.1 United States Flu RNA Vaccines Sales in Value, by Type (2017, 2022 & 2028)
        2.3.2 United States Flu RNA Vaccines Sales in Volume, by Type (2017, 2022 & 2028)
        2.3.3 United States Flu RNA Vaccines Average Selling Price (ASP) by Type (2017, 2022 & 2028)

 3 Market by Application
    3.1 Flu RNA Vaccines Market Segment by Application
        3.1.1 Hospitals
        3.1.2 Vaccination Center
        3.1.3 Specialized Clinics
        3.1.4 Hospital Pharmacy
        3.1.5 Others
    3.2 Global Flu RNA Vaccines Market Size by Application
        3.2.1 Global Flu RNA Vaccines Sales in Value, by Application (2017, 2022 & 2028)
        3.2.2 Global Flu RNA Vaccines Sales in Volume, by Application (2017, 2022 & 2028)
        3.3.3 Global Flu RNA Vaccines Average Selling Price (ASP) by Application (2017, 2022 & 2028)
    3.3 United States Flu RNA Vaccines Market Size by Application
        3.3.1 United States Flu RNA Vaccines Sales in Value, by Application (2017, 2022 & 2028)
        3.3.2 United States Flu RNA Vaccines Sales in Volume, by Application (2017, 2022 & 2028)
        3.3.3 United States Flu RNA Vaccines Average Selling Price (ASP) by Application (2017, 2022 & 2028)

 4 Global Flu RNA Vaccines Competitor Landscape by Company
    4.1 Global Flu RNA Vaccines Market Size by Company
        4.1.1 Top Global Flu RNA Vaccines Manufacturers Ranked by Revenue (2021)
        4.1.2 Global Flu RNA Vaccines Revenue by Manufacturer (2017-2022)
        4.1.3 Global Flu RNA Vaccines Sales by Manufacturer (2017-2022)
        4.1.4 Global Flu RNA Vaccines Price by Manufacturer (2017-2022)
    4.2 Global Flu RNA Vaccines Concentration Ratio (CR)
        4.2.1 Flu RNA Vaccines Market Concentration Ratio (CR) (2017-2022)
        4.2.2 Global Top 5 and Top 10 Largest Manufacturers of Flu RNA Vaccines in 2021
        4.2.3 Global Flu RNA Vaccines Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
    4.3 Global Flu RNA Vaccines Manufacturing Base Distribution, Product Type
        4.3.1 Global Flu RNA Vaccines Manufacturers, Headquarters and Distribution of Producing Region
        4.3.2 Manufacturers Flu RNA Vaccines Product Type
        4.3.3 Date of International Manufacturers Enter into Flu RNA Vaccines Market
    4.4 Manufacturers Mergers & Acquisitions, Expansion Plans
    4.5 United States Flu RNA Vaccines Market Size by Company
        4.5.1 Top Flu RNA Vaccines Players in United States, Ranked by Revenue (2021)
        4.5.2 United States Flu RNA Vaccines Revenue by Players (2020, 2021 & 2022)
        4.5.3 United States Flu RNA Vaccines Sales by Players (2020, 2021 & 2022)

 5 Global Flu RNA Vaccines Market Size by Region
    5.1 Global Flu RNA Vaccines Market Size by Region: 2017 VS 2022 VS 2028
    5.2 Global Flu RNA Vaccines Market Size in Volume by Region (2017-2028)
        5.2.1 Global Flu RNA Vaccines Sales in Volume by Region: 2017-2022
        5.2.2 Global Flu RNA Vaccines Sales in Volume Forecast by Region (2023-2028)
    5.3 Global Flu RNA Vaccines Market Size in Value by Region (2017-2028)
        5.3.1 Global Flu RNA Vaccines Sales in Value by Region: 2017-2022
        5.3.2 Global Flu RNA Vaccines Sales in Value by Region: 2023-2028

 6 Segment in Region Level & Country Level
    6.1 North America
        6.1.1 North America Flu RNA Vaccines Market Size YoY Growth 2017-2028
        6.1.2 North America Flu RNA Vaccines Market Facts & Figures by Country (2017, 2022 & 2028)
        6.1.3 United States
        6.1.4 Canada
    6.2 Asia-Pacific
        6.2.1 Asia-Pacific Flu RNA Vaccines Market Size YoY Growth 2017-2028
        6.2.2 Asia-Pacific Flu RNA Vaccines Market Facts & Figures by Region (2017, 2022 & 2028)
        6.2.3 China
        6.2.4 Japan
        6.2.5 South Korea
        6.2.6 India
        6.2.7 Australia
        6.2.8 China Taiwan
        6.2.9 Indonesia
        6.2.10 Thailand
        6.2.11 Malaysia
    6.3 Europe
        6.3.1 Europe Flu RNA Vaccines Market Size YoY Growth 2017-2028
        6.3.2 Europe Flu RNA Vaccines Market Facts & Figures by Country (2017, 2022 & 2028)
        6.3.3 Germany
        6.3.4 France
        6.3.5 U.K.
        6.3.6 Italy
        6.3.7 Russia
    6.4 Latin America
        6.4.1 Latin America Flu RNA Vaccines Market Size YoY Growth 2017-2028
        6.4.2 Latin America Flu RNA Vaccines Market Facts & Figures by Country (2017, 2022 & 2028)
        6.4.3 Mexico
        6.4.4 Brazil
        6.4.5 Argentina
        6.4.6 Colombia
    6.5 Middle East and Africa
        6.5.1 Middle East and Africa Flu RNA Vaccines Market Size YoY Growth 2017-2028
        6.5.2 Middle East and Africa Flu RNA Vaccines Market Facts & Figures by Country (2017, 2022 & 2028)
        6.5.3 Turkey
        6.5.4 Saudi Arabia
        6.5.5 UAE

 7 Company Profiles
    7.1 Sanofi Pasteur Inc.
        7.1.1 Sanofi Pasteur Inc. Corporation Information
        7.1.2 Sanofi Pasteur Inc. Description and Business Overview
        7.1.3 Sanofi Pasteur Inc. Flu RNA Vaccines Sales, Revenue and Gross Margin (2017-2022)
        7.1.4 Sanofi Pasteur Inc. Flu RNA Vaccines Products Offered
        7.1.5 Sanofi Pasteur Inc. Recent Development
    7.2 AstraZeneca
        7.2.1 AstraZeneca Corporation Information
        7.2.2 AstraZeneca Description and Business Overview
        7.2.3 AstraZeneca Flu RNA Vaccines Sales, Revenue and Gross Margin (2017-2022)
        7.2.4 AstraZeneca Flu RNA Vaccines Products Offered
        7.2.5 AstraZeneca Recent Development
    7.3 CSL Ltd.
        7.3.1 CSL Ltd. Corporation Information
        7.3.2 CSL Ltd. Description and Business Overview
        7.3.3 CSL Ltd. Flu RNA Vaccines Sales, Revenue and Gross Margin (2017-2022)
        7.3.4 CSL Ltd. Flu RNA Vaccines Products Offered
        7.3.5 CSL Ltd. Recent Development
    7.4 Abbott
        7.4.1 Abbott Corporation Information
        7.4.2 Abbott Description and Business Overview
        7.4.3 Abbott Flu RNA Vaccines Sales, Revenue and Gross Margin (2017-2022)
        7.4.4 Abbott Flu RNA Vaccines Products Offered
        7.4.5 Abbott Recent Development
    7.5 GlaxoSmithKline Plc.
        7.5.1 GlaxoSmithKline Plc. Corporation Information
        7.5.2 GlaxoSmithKline Plc. Description and Business Overview
        7.5.3 GlaxoSmithKline Plc. Flu RNA Vaccines Sales, Revenue and Gross Margin (2017-2022)
        7.5.4 GlaxoSmithKline Plc. Flu RNA Vaccines Products Offered
        7.5.5 GlaxoSmithKline Plc. Recent Development
    7.6 Serum Institute of India Pvt. Ltd.
        7.6.1 Serum Institute of India Pvt. Ltd. Corporation Information
        7.6.2 Serum Institute of India Pvt. Ltd. Description and Business Overview
        7.6.3 Serum Institute of India Pvt. Ltd. Flu RNA Vaccines Sales, Revenue and Gross Margin (2017-2022)
        7.6.4 Serum Institute of India Pvt. Ltd. Flu RNA Vaccines Products Offered
        7.6.5 Serum Institute of India Pvt. Ltd. Recent Development
    7.7 Pfizer
        7.7.1 Pfizer Corporation Information
        7.7.2 Pfizer Description and Business Overview
        7.7.3 Pfizer Flu RNA Vaccines Sales, Revenue and Gross Margin (2017-2022)
        7.7.4 Pfizer Flu RNA Vaccines Products Offered
        7.7.5 Pfizer Recent Development
    7.8 BioNTech
        7.8.1 BioNTech Corporation Information
        7.8.2 BioNTech Description and Business Overview
        7.8.3 BioNTech Flu RNA Vaccines Sales, Revenue and Gross Margin (2017-2022)
        7.8.4 BioNTech Flu RNA Vaccines Products Offered
        7.8.5 BioNTech Recent Development
    7.9 F.Hoffman La Roche Ltd
        7.9.1 F.Hoffman La Roche Ltd Corporation Information
        7.9.2 F.Hoffman La Roche Ltd Description and Business Overview
        7.9.3 F.Hoffman La Roche Ltd Flu RNA Vaccines Sales, Revenue and Gross Margin (2017-2022)
        7.9.4 F.Hoffman La Roche Ltd Flu RNA Vaccines Products Offered
        7.9.5 F.Hoffman La Roche Ltd Recent Development
    7.10 Novartis
        7.10.1 Novartis Corporation Information
        7.10.2 Novartis Description and Business Overview
        7.10.3 Novartis Flu RNA Vaccines Sales, Revenue and Gross Margin (2017-2022)
        7.10.4 Novartis Flu RNA Vaccines Products Offered
        7.10.5 Novartis Recent Development
    7.11 Sinnovac Biotech Ltd
        7.11.1 Sinnovac Biotech Ltd Corporation Information
        7.11.2 Sinnovac Biotech Ltd Description and Business Overview
        7.11.3 Sinnovac Biotech Ltd Flu RNA Vaccines Sales, Revenue and Gross Margin (2017-2022)
        7.11.4 Sinnovac Biotech Ltd Flu RNA Vaccines Products Offered
        7.11.5 Sinnovac Biotech Ltd Recent Development
    7.12 Moderna Therapeutics
        7.12.1 Moderna Therapeutics Corporation Information
        7.12.2 Moderna Therapeutics Description and Business Overview
        7.12.3 Moderna Therapeutics Flu RNA Vaccines Sales, Revenue and Gross Margin (2017-2022)
        7.12.4 Moderna Therapeutics Products Offered
        7.12.5 Moderna Therapeutics Recent Development
    7.13 CureVac
        7.13.1 CureVac Corporation Information
        7.13.2 CureVac Description and Business Overview
        7.13.3 CureVac Flu RNA Vaccines Sales, Revenue and Gross Margin (2017-2022)
        7.13.4 CureVac Products Offered
        7.13.5 CureVac Recent Development

 8 Industry Chain and Sales Channels Analysis
    8.1 Flu RNA Vaccines Industry Chain Analysis
    8.2 Flu RNA Vaccines Key Raw Materials
        8.2.1 Key Raw Materials
        8.2.2 Flu RNA Vaccines Distributors
    8.3 Flu RNA Vaccines Production Mode & Process
    8.4 Flu RNA Vaccines Sales and Marketing
        8.4.1 Flu RNA Vaccines Sales Channels
        8.4.2 Flu RNA Vaccines Distributors
    8.5 Flu RNA Vaccines Customers

 9 Research Findings and Conclusion

 10 Appendix
    10.1 Research Methodology
        10.1.1 Methodology/Research Approach
        10.1.2 Data Source
    10.2 Author Details
    10.3 Disclaimer

List of Tables
    Table 1. Flu RNA Vaccines CAGR in Value, United States VS Global, 2017 VS 2022 VS 2028
    Table 2. Flu RNA Vaccines Market Trends
    Table 3. Flu RNA Vaccines Market Drivers
    Table 4. Flu RNA Vaccines Market Challenges
    Table 5. Flu RNA Vaccines Market Restraints
    Table 6. Global Flu RNA Vaccines Sales by Type: 2017 VS 2022 VS 2028 (US$ Million)
    Table 7. United States Flu RNA Vaccines Sales by Type: 2017 VS 2022 VS 2028 (US$ Million)
    Table 8. Global Flu RNA Vaccines Sales by Application: 2017 VS 2022 VS 2028 (US$ Million)
    Table 9. United States Flu RNA Vaccines Sales by Application: 2017 VS 2022 VS 2028 (US$ Million)
    Table 10. Top Flu RNA Vaccines Manufacturers in Global Market, Ranking by Revenue (2021)
    Table 11. Global Flu RNA Vaccines Revenue by Manufacturer, (US$ Million), 2017-2022
    Table 12. Global Flu RNA Vaccines Revenue Share by Manufacturer, 2017-2022
    Table 13. Global Flu RNA Vaccines Sales by Manufacturer, (K Units), 2017-2022
    Table 14. Global Flu RNA Vaccines Sales Share by Manufacturer, 2017-2022
    Table 15. Global Flu RNA Vaccines Price by Manufacturer (2017-2022) & (US$/Unit)
    Table 16. Global Flu RNA Vaccines Manufacturers Market Concentration Ratio (CR5 and HHI)
    Table 17. Global Flu RNA Vaccines by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Flu RNA Vaccines as of 2021)
    Table 18. Top Players of Flu RNA Vaccines in Global Market, Headquarters and Distribution of Producing Region
    Table 19. Manufacturers Flu RNA Vaccines Product Type
    Table 20. Date of International Manufacturers Enter into Flu RNA Vaccines Market
    Table 21. Manufacturers Mergers & Acquisitions, Expansion Plans
    Table 22. Top Flu RNA Vaccines Players in United States Market, Ranking by Revenue (2021)
    Table 23. United States Flu RNA Vaccines Revenue by Players, (US$ Million), 2020, 2021 & 2022
    Table 24. United States Flu RNA Vaccines Revenue Share by Players, 2020, 2021 & 2022
    Table 25. United States Flu RNA Vaccines Sales by Players, (K Units), 2020, 2021 & 2022
    Table 26. United States Flu RNA Vaccines Sales Share by Players, 2020, 2021 & 2022
    Table 27. Global Flu RNA Vaccines Market Size by Region (US$ Million): 2017 VS 2022 VS 2028
    Table 28. Global Flu RNA Vaccines Sales in Volume by Region (2017-2022) & (K Units)
    Table 29. Global Flu RNA Vaccines Sales in Volume Forecast by Region (2023-2028) & (K Units)
    Table 30. Global Flu RNA Vaccines Sales in Value by Region (2017-2022) & (US$ Million)
    Table 31. Global Flu RNA Vaccines Sales in Value Forecast by Region (2023-2028) & (US$ Million)
    Table 32. North America Flu RNA Vaccines Sales in Volume by Country (2017-2028) & (K Units)
    Table 33. North America Flu RNA Vaccines Sales in Value by Country (2017-2028) & (US$ Million)
    Table 34. Asia Pacific Flu RNA Vaccines Sales in Volume by Region (2017-2028) & (K Units)
    Table 35. Asia Pacific Flu RNA Vaccines Sales in Value by Region (2017-2028) & (US$ Million)
    Table 36. Europe Flu RNA Vaccines Sales in Volume by Country (2017-2028) & (K Units)
    Table 37. Europe Flu RNA Vaccines Sales in Value by Country (2017-2028) & (US$ Million)
    Table 38. Latin America Flu RNA Vaccines Sales in Volume by Country (2017-2028) & (K Units)
    Table 39. Latin Americaa Flu RNA Vaccines Sales in Value by Country (2017-2028) & (US$ Million)
    Table 40. Middle East and Africa Flu RNA Vaccines Sales in Volume by Country (2017-2028) & (K Units)
    Table 41. Middle East and Africa Flu RNA Vaccines Sales in Value by Country (2017-2028) & (US$ Million)
    Table 42. Sanofi Pasteur Inc. Corporation Information
    Table 43. Sanofi Pasteur Inc. Description and Business Overview
    Table 44. Sanofi Pasteur Inc. Flu RNA Vaccines Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
    Table 45. Sanofi Pasteur Inc. Flu RNA Vaccines Product
    Table 46. Sanofi Pasteur Inc. Recent Development
    Table 47. AstraZeneca Corporation Information
    Table 48. AstraZeneca Description and Business Overview
    Table 49. AstraZeneca Flu RNA Vaccines Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
    Table 50. AstraZeneca Product
    Table 51. AstraZeneca Recent Development
    Table 52. CSL Ltd. Corporation Information
    Table 53. CSL Ltd. Description and Business Overview
    Table 54. CSL Ltd. Flu RNA Vaccines Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
    Table 55. CSL Ltd. Product
    Table 56. CSL Ltd. Recent Development
    Table 57. Abbott Corporation Information
    Table 58. Abbott Description and Business Overview
    Table 59. Abbott Flu RNA Vaccines Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
    Table 60. Abbott Product
    Table 61. Abbott Recent Development
    Table 62. GlaxoSmithKline Plc. Corporation Information
    Table 63. GlaxoSmithKline Plc. Description and Business Overview
    Table 64. GlaxoSmithKline Plc. Flu RNA Vaccines Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
    Table 65. GlaxoSmithKline Plc. Product
    Table 66. GlaxoSmithKline Plc. Recent Development
    Table 67. Serum Institute of India Pvt. Ltd. Corporation Information
    Table 68. Serum Institute of India Pvt. Ltd. Description and Business Overview
    Table 69. Serum Institute of India Pvt. Ltd. Flu RNA Vaccines Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
    Table 70. Serum Institute of India Pvt. Ltd. Product
    Table 71. Serum Institute of India Pvt. Ltd. Recent Development
    Table 72. Pfizer Corporation Information
    Table 73. Pfizer Description and Business Overview
    Table 74. Pfizer Flu RNA Vaccines Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
    Table 75. Pfizer Product
    Table 76. Pfizer Recent Development
    Table 77. BioNTech Corporation Information
    Table 78. BioNTech Description and Business Overview
    Table 79. BioNTech Flu RNA Vaccines Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
    Table 80. BioNTech Product
    Table 81. BioNTech Recent Development
    Table 82. F.Hoffman La Roche Ltd Corporation Information
    Table 83. F.Hoffman La Roche Ltd Description and Business Overview
    Table 84. F.Hoffman La Roche Ltd Flu RNA Vaccines Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
    Table 85. F.Hoffman La Roche Ltd Product
    Table 86. F.Hoffman La Roche Ltd Recent Development
    Table 87. Novartis Corporation Information
    Table 88. Novartis Description and Business Overview
    Table 89. Novartis Flu RNA Vaccines Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
    Table 90. Novartis Product
    Table 91. Novartis Recent Development
    Table 92. Sinnovac Biotech Ltd Corporation Information
    Table 93. Sinnovac Biotech Ltd Description and Business Overview
    Table 94. Sinnovac Biotech Ltd Flu RNA Vaccines Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
    Table 95. Sinnovac Biotech Ltd Product
    Table 96. Sinnovac Biotech Ltd Recent Development
    Table 97. Moderna Therapeutics Corporation Information
    Table 98. Moderna Therapeutics Description and Business Overview
    Table 99. Moderna Therapeutics Flu RNA Vaccines Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
    Table 100. Moderna Therapeutics Product
    Table 101. Moderna Therapeutics Recent Development
    Table 102. CureVac Corporation Information
    Table 103. CureVac Description and Business Overview
    Table 104. CureVac Flu RNA Vaccines Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
    Table 105. CureVac Product
    Table 106. CureVac Recent Development
    Table 107. Key Raw Materials Lists
    Table 108. Raw Materials Key Suppliers Lists
    Table 109. Flu RNA Vaccines Customers List
    Table 110. Flu RNA Vaccines Distributors List
    Table 111. Research Programs/Design for This Report
    Table 112. Key Data Information from Secondary Sources
    Table 113. Key Data Information from Primary Sources
List of Figures
    Figure 1. Flu RNA Vaccines Product Picture
    Figure 2. Global Flu RNA Vaccines Revenue, (US$ Million), 2017 VS 2022 VS 2028
    Figure 3. Global Flu RNA Vaccines Market Size 2017-2028 (US$ Million)
    Figure 4. Global Flu RNA Vaccines Sales 2017-2028 (K Units)
    Figure 5. United States Flu RNA Vaccines Revenue, (US$ Million), 2017 VS 2022 VS 2028
    Figure 6. United States Flu RNA Vaccines Market Size 2017-2028 (US$ Million)
    Figure 7. United States Flu RNA Vaccines Sales 2017-2028 (K Units)
    Figure 8. United States Flu RNA Vaccines Market Share in Global, in Value (US$ Million) 2017-2028
    Figure 9. United States Flu RNA Vaccines Market Share in Global, in Volume (K Units) 2017-2028
    Figure 10. Flu RNA Vaccines Report Years Considered
    Figure 11. Product Picture of Non-Replicating mRNA
    Figure 12. Product Picture of In Vivo Self-Replicating mRNA
    Figure 13. Product Picture of In Vitro Dendritic Cell Non-Replicating mRNA Vaccine
    Figure 14. Product Picture of Others
    Figure 15. Global Flu RNA Vaccines Market Share by Type in 2022 & 2028
    Figure 16. Global Flu RNA Vaccines Sales in Value by Type (2017-2028) & (US$ Million)
    Figure 17. Global Flu RNA Vaccines Sales Market Share in Value by Type (2017-2028)
    Figure 18. Global Flu RNA Vaccines Sales by Type (2017-2028) & (K Units)
    Figure 19. Global Flu RNA Vaccines Sales Market Share in Volume by Type (2017-2028)
    Figure 20. Global Flu RNA Vaccines Price by Type (2017-2028) & (US$/Unit)
    Figure 21. United States Flu RNA Vaccines Market Share by Type in 2022 & 2028
    Figure 22. United States Flu RNA Vaccines Sales in Value by Type (2017-2028) & (US$ Million)
    Figure 23. United States Flu RNA Vaccines Sales Market Share in Value by Type (2017-2028)
    Figure 24. United States Flu RNA Vaccines Sales by Type (2017-2028) & (K Units)
    Figure 25. United States Flu RNA Vaccines Sales Market Share in Volume by Type (2017-2028)
    Figure 26. United States Flu RNA Vaccines Price by Type (2017-2028) & (US$/Unit)
    Figure 27. Product Picture of Hospitals
    Figure 28. Product Picture of Vaccination Center
    Figure 29. Product Picture of Specialized Clinics
    Figure 30. Product Picture of Hospital Pharmacy
    Figure 31. Product Picture of Others
    Figure 32. Global Flu RNA Vaccines Market Share by Application in 2022 & 2028
    Figure 33. Global Flu RNA Vaccines Sales in Value by Application (2017-2028) & (US$ Million)
    Figure 34. Global Flu RNA Vaccines Sales Market Share in Value by Application (2017-2028)
    Figure 35. Global Flu RNA Vaccines Sales by Application (2017-2028) & (K Units)
    Figure 36. Global Flu RNA Vaccines Sales Market Share in Volume by Application (2017-2028)
    Figure 37. Global Flu RNA Vaccines Price by Application (2017-2028) & (US$/Unit)
    Figure 38. United States Flu RNA Vaccines Market Share by Application in 2022 & 2028
    Figure 39. United States Flu RNA Vaccines Sales in Value by Application (2017-2028) & (US$ Million)
    Figure 40. United States Flu RNA Vaccines Sales Market Share in Value by Application (2017-2028)
    Figure 41. United States Flu RNA Vaccines Sales by Application (2017-2028) & (K Units)
    Figure 42. United States Flu RNA Vaccines Sales Market Share in Volume by Application (2017-2028)
    Figure 43. United States Flu RNA Vaccines Price by Application (2017-2028) & (US$/Unit)
    Figure 44. North America Flu RNA Vaccines Sales in Volume Growth Rate 2017-2028 (K Units)
    Figure 45. North America Flu RNA Vaccines Sales in Value Growth Rate 2017-2028 (US$ Million)
    Figure 46. United States Flu RNA Vaccines Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 47. Canada Flu RNA Vaccines Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 48. Europe Flu RNA Vaccines Sales in Volume Growth Rate 2017-2028 (K Units)
    Figure 49. Europe Flu RNA Vaccines Sales in Value Growth Rate 2017-2028 (US$ Million)
    Figure 50. Germany Flu RNA Vaccines Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 51. France Flu RNA Vaccines Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 52. U.K. Flu RNA Vaccines Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 53. Italy Flu RNA Vaccines Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 54. Russia Flu RNA Vaccines Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 55. Asia-Pacific Flu RNA Vaccines Sales in Volume Growth Rate 2017-2028 (K Units)
    Figure 56. Asia-Pacific Flu RNA Vaccines Sales in Value Growth Rate 2017-2028 (US$ Million)
    Figure 57. China Flu RNA Vaccines Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 58. Japan Flu RNA Vaccines Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 59. South Korea Flu RNA Vaccines Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 60. India Flu RNA Vaccines Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 61. Australia Flu RNA Vaccines Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 62. China Taiwan Flu RNA Vaccines Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 63. Indonesia Flu RNA Vaccines Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 64. Thailand Flu RNA Vaccines Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 65. Malaysia Flu RNA Vaccines Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 66. Latin America Flu RNA Vaccines Sales in Volume Growth Rate 2017-2028 (K Units)
    Figure 67. Latin America Flu RNA Vaccines Sales in Value Growth Rate 2017-2028 (US$ Million)
    Figure 68. Mexico Flu RNA Vaccines Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 69. Brazil Flu RNA Vaccines Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 70. Argentina Flu RNA Vaccines Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 71. Colombia Flu RNA Vaccines Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 72. Middle East & Africa Flu RNA Vaccines Sales in Volume Growth Rate 2017-2028 (K Units)
    Figure 73. Middle East & Africa Flu RNA Vaccines Sales in Value Growth Rate 2017-2028 (US$ Million)
    Figure 74. Turkey Flu RNA Vaccines Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 75. Saudi Arabia Flu RNA Vaccines Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 76. UAE Flu RNA Vaccines Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 77. Flu RNA Vaccines Value Chain
    Figure 78. Flu RNA Vaccines Production Process
    Figure 79. Channels of Distribution
    Figure 80. Distributors Profiles
    Figure 81. Bottom-up and Top-down Approaches for This Report
    Figure 82. Data Triangulation
    Figure 83. Key Executives Interviewed

The major advantage of Flu RNA Vaccines is that scientist need not to use the live cells for the vaccine preparation as such the RNA can be produced in the laboratory from a DNA template using readily available materials which can be a easy and fast weapon to fight against the new outbreaks and the existing infectious diseases.

Market Analysis and Insights: Global and United States Flu RNA Vaccines Market

This report focuses on global and United States Flu RNA Vaccines market, also covers the segmentation data of other regions in regional level and county level.

In United States the Flu RNA Vaccines market size is expected to grow from US$ million in 2021 to US$ million by 2028, at a CAGR of % during the forecast period 2022-2028.

Segment by Type
Non-Replicating mRNA
In Vivo Self-Replicating mRNA
In Vitro Dendritic Cell Non-Replicating mRNA Vaccine
Others

Segment by Application
Hospitals
Vaccination Center
Specialized Clinics
Hospital Pharmacy
Others

Industry: Pharma & Healthcare

Published: 2022-05-09

Pages: 104 Pages

Report ld: 355758

Request Sample

Pre-Order Enquiry

CHOOSE LICENSE TYPE

Single User License

USD 4350.00

Multi Users License

USD 6525.00

Corporate Users License

USD 8700.00

/uploads/payment/payIcon/masterCard-01.svg

/uploads/payment/payIcon/american-express-01.svg

/uploads/payment/payIcon/diners-club-01.svg

/uploads/payment/payIcon/discover-4-01.svg

Add to Cart

Buy Now

A comprehensive and in-depth analysis of current industry data on markets, competitors and suppliers.

In-depth research on key industry players and analysis of production and sales operations.

Objective forecasts of future trends in the industry.

Speak To Our Analyst >>

WHAT QYRESEARCH OFFER?